SENDAI, Japan, Aug. 23 /PRNewswire/ -- OrbusNeich today reported that optical coherence tomography (OCT) evaluation of a patient with anterior ST-elevation myocardial infarction (STEMI) who received two of the company's Genous Bio-engineered R stents showed 100 percent coverage of the stent struts and complete neointimal coverage 26 days post-implantation.
Stephen Wai-Luen Lee, M.B.B.S., of the Queen Mary Hospital in Hong Kong presented the findings in a presentation, "Genous Combo – The Latest of Novel Devices in the Evolution of the Coronary Intervention," as part of a symposium at the Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics.
Following a diagnosis of acute thrombotic occlusion of the proximal left anterior descending artery (LAD), with critical lesions identified in the proximal and mid LAD and a chronic total occlusion (CTO) of the proximal right coronary artery (RCA), the patient, a 62-year-old male, received two 2.5 mm diameter Genous Bio-engineered R stents. The proximal stent was 23 mm in length, and the distal stent was 13 mm in length. At 26 days post-implantation, physicians conducted an OCT assessment when a staged procedure was performed to the CTO on the RCA with implantation of an additional 2.5 mm diameter by 23 mm length Genous Bio-engineered R stent.
"This is the first documentation of complete endothelialization after 26 days of Genous stent implantation, showing the pro-healing effect in vivo," said Prof. Lee.
Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, SafeCut™, Sapphire™, Sapphire NC, Avita™, Avita HP and Lumina™. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.